|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterised by hypercalcaemia and parathormone increase.
|
30459009 |
2020 |
|
Hyperparathyroidism, Primary
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We assessed if cerebrovascular function is impaired in PHPT, improves post-parathyroidectomy and is associated with PTH level and cognitive dysfunction.
|
31621051 |
2020 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recently, normocalcemic (NC) and normohormonal (NH) variants of primary hyperparathyroidism (pHPT) have been described, with distinct biochemical profiles from the typical high serum calcium and parathyroid hormone (PTH) levels.
|
31511943 |
2020 |
|
Hyperparathyroidism, Primary
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
LNP patients had a milder form of pHPT (Ca<sup>2+</sup> 2.63 vs. 2.68 P < 0.05) with a smaller PTH and Ca<sup>2+</sup> drop post-operatively.
|
31773224 |
2020 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
An abnormal parathyroid was defined by a gland weight of ≥50 mg. A concurrent serum calcium >10.2 mg/dL and parathyroid hormone >40 pg/mL was defined as persistent PHPT if present <6 mo and recurrent PHPT if present ≥6 mo postoperatively after initial normocalcemia.
|
31635835 |
2020 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism (PHPT) is a common endocrine disorder, resulting from the autonomous production of parathyroid hormone from 1 or more abnormal parathyroid glands.
|
31255197 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Original articles reporting complications and diagnostic performance of FNA-PTH in biochemically and histopathologically diagnosed PHPT were selected.
|
31311003 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
The primary cause of PHPT is a benign overgrowth of parathyroid tissue causing excessive secretion of parathyroid hormone.
|
30979723 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
The increasing use of serum PTH assay in the set of the diagnostic workout in patients with osteoporosis has identified patients with features of surgically confirmed primary hyperparathyroidism (PHPT) associated with persistent normal serum calcium levels, which has been recognized as a distinct entity from hypercalcemic PHPT (HPHPT) by the last international consensus.
|
30641527 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Minimally Invasive Parathyroidectomy without Intraoperative PTH Performed after Positive Ultrasonography as the only Diagnostic Method in Patients with Primary Hyperparathyroidism.
|
30847526 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Importance of Parathyroid Hormone Needle Aspiration Washout in Adenoma Localization in Primary Hyperparathyroidism.
|
30834899 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Primary hyperparathyroidism (pHPT) is the third most common endocrine disease and is characterized by hypercalcaemia and elevated or inappropriately 'normal' levels of the parathyroid hormone (PTH).
|
30289185 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by dysregulation of parathyroid hormone release.
|
30475215 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Intraoperative parathyroid hormone testing in primary hyperparathyroidism surgery: time for giving up?
|
30357494 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Their regression after PTH reduction suggested the diagnosis of brown tumors due to severe HPT.
|
30905030 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Among patients with Ca/P ratio above 3.56, the thresholds of 10.3 mg/dL (2.6 mmol/L) for serum Ca (sensitivity 93%; specificity 98%) and 80.5 pg/mL for PTH (sensitivity 91%; specificity 91%) were defined for the specific diagnosis of PHPT.
|
30796757 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mortality in PHPT was associated with older age (P < 0.008), social deprivation (P = 0.028), and adjusted calcium (P = 0.009) but not independently with PTH at diagnosis.
|
30916764 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
Parathyroid hormone (PTH) related hypercalcaemia is most commonly caused by primary hyperparathyroidism (PHPT) and more rarely by familial hypocalciuric hypercalcaemia (FHH).
|
31797261 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
We found a positive correlation of preoperative NLR with calcium and PTH levels in PHPT patients.
|
31360183 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
In 2,522 untreated patients with classic PHPT, patients most frequently transitioned to the normal calcium with elevated PTH group (n = 1,257, 49.8%).
|
30720335 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Normalized outcomes for both PTH and calcium levels were achieved in 19 of 22 (86.36%) patients with PHPT.
|
30888479 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Elevated PTH levels are common after parathyroidectomy for normocalcemic PHPT.
|
30406488 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
For classic primary hyperparathyroidism (PHPT), the type of PTH assay used will not affect diagnosis or management because the precise concentration of PTH is less relevant.
|
31081903 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Primary hyperparathyroidism (PHPT) is a condition where elevated PTH levels lead to bone loss, in part through increased production of the osteoclastogenic factor IL-17A, by bone marrow (BM) T-helper 17 (Th17) cells, a subset of helper CD4+ T cells.
|
30399207 |
2019 |
|
Hyperparathyroidism, Primary
|
0.200 |
Biomarker
|
disease |
BEFREE |
To confirm the in vivo impact of PTH on irisin, we compared irisin serum concentrations in postmenopausal women with primary hyperparathyroidism (PHPT) and control subjects.
|
30759249 |
2019 |